Hakutulokset - Libor Havel

Tarkenna hakua
  1. 1
    Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

    Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report Tekijä Yuanbin Chen, Luis Paz‐Ares, Niels Reinmuth, Marina Chiara Garassino, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Francesco Verderame, Libor Havel, György Losonczy, Nikolay Conev, Katsuyuki Hotta, Jun Ho Ji, Stuart Spencer, Tapashi Dalvi, Haiyi Jiang, Jonathan W. Goldman

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)

    Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with... Tekijä Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, Tommaso De Pas, M. Zieliński, M.S. Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Hironao Nakayama, Libor Havel, Haruhiko Kondo, Tetsuya Mitsudomi, Kostas Zarogoulidis, Oleg Gladkov, Bart Spiessens, Vincent Brichard, Channa Debruyne, P. Therasse, Nasser K. Altorki

    Julkaistu 2014
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

    LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or plac... Tekijä Tina Cascone, Mark M. Awad, J.D. Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Jarosław Kużdżał, Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, Christoph Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, M. Provencio Pulla

    Julkaistu 2023
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

    PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN Tekijä Luis Paz‐Ares, Jonathan W. Goldman, Marina Chiara Garassino, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Katsuyuki Hotta, Jun Ho Ji, Maximilian J. Hochmair, Олександр Войтко, Libor Havel, Artem Poltoratskiy, György Losonczy, Niels Reinmuth, Yashaswi Shrestha, Nikunj Patel, Helen Mann, Haiyi Jiang, Mustafa Özgüroğlu, Yuanbin Chen

    Julkaistu 2019
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

    VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Ra... Tekijä L. Paz-Ares, E O’Brien, M. Mauer, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martínez‐Martí, Martin Faehling, Masahiro Tsuboi, JS Lee, Kouichi Nakagawa, Jiong Yang, S.M. Keller, Nitish Jha, Sandrine Marréaud, R.A. Stahel, Solange Peters, Benjamin Besse

    Julkaistu 2022
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Tekijä Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled... Tekijä Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen, Mustafa Özgüroğlu, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Katsuyuki Hotta, Jun Ho Ji, Maximilian J. Hochmair, Олександр Войтко, Libor Havel, Artem Poltoratskiy, György Losonczy, Niels Reinmuth, Nikunj Patel, Peter J. Laud, Norah J. Shire, Haiyi Jiang, Luis Paz‐Ares

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

    Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN Tekijä Luis Paz‐Ares, Y Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, E. Musso, Libor Havel, Igor Bondarenko, György Losonczy, Nikolay Conev, Helen Mann, Tapashi Dalvi, Haiyi Jiang, Jonathan W. Goldman

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

    Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial Tekijä Hossein Borghaei, Kenneth J. O’Byrne, Luis Paz‐Ares, T. Ciuleanu, Xiaochu Yu, Adam Płużański, Adnan Nagrial, Libor Havel, Rubén Dario Kowalyszyn, Clarisse Audigier-Valette, Julie R. Brahmer, Martin Reck, S.S. Ramalingam, Li Zhang, Ives Ntambwe, Sridhar K. Rabindran, Faith E. Nathan, David Balli, Yi‐Long Wu

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

    LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 fi... Tekijä Luis Paz‐Ares, Tudor‐Eliade Ciuleanu, Xiaolu Yu, Pamela Salman, Adam Płużański, Adnan Nagrial, Libor Havel, Rubén Dario Kowalyszyn, Clarisse Audigier-Valette, Yi‐Long Wu, Hossein Borghaei, Matthew D. Hellmann, Julie R. Brahmer, Martin Reck, Sundar Ramalingam, L. Zhang, Prabhu Bhagavatheeswaran, Faith E. Nathan, Kenneth J. O’Byrne

    Julkaistu 2019
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Tekijä Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor‐Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

    Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden Tekijä Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Nikolay Conev, Igor Bondarenko, Libor Havel, György Losonczy, Mingchao Xie, Zhongwu Lai, Nadia Godin-Heymann, Helen Mann, Haiyi Jiang, Yashaswi Shrestha, Jonathan W. Goldman

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

    Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer Tekijä Vincent D. de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brčić, Reinhard Büttner, Gabriela Fernandes, Libor Havel, Maximilian J. Hochmair, Paul Hofman, Annelies Janssens, Léon C.L.T. van Kempen, Izidor Kern, José Carlos Machado, Katja Mohorčič, Sanjay Popat, Aleš Ryška, Jürgen Wolf, Ed Schuuring, Anthonie J. van der Wekken

    Julkaistu 2024
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)

    9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs) Tekijä Chee Khoon Lee, Ying Cheng, К. К. Лактионов, S-W. Kim, Terufumi Kato, J. Wang, Paul Mitchell, Vladimir P. Bermudez, Shoichi Kuyama, Jerry Y. Tan Chun Bing, J.E. Cundom, G.D.J. Pinto, Frances A. Shepherd, L. Poole, Muna Albayaty, Neha P. Amin, Kunihiko Kobayashi, Libor Havel, Jhanelle E. Gray

    Julkaistu 2024
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets)

    P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets) Tekijä Jonathan W. Goldman, Lucio Crinò, Everett E. Vokes, Esther Holgado, Karen L. Reckamp, Adam Płużański, David R. Spigel, Martin Kohlhäeufl, Marina Chiara Garassino, Laura QM Chow, Scott Gettinger, David E. Gerber, Libor Havel, Suresh S. Ramalingam, Grace K. Dy, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Gilberto Lopes

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

    OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results Tekijä Stephen V. Liu, Rafał Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian J. Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, R.B. Caro, G Losonczy, J.-S. Lee, D. Kowalski, Zoran Andrić, Raffaele Califano, Andrea Veatch, Gregory J. Gerstner, Marta Batus, S. Morris, M. Kaul, M. Siddiqui, H. Li, W. Zhang, Barzin Y. Nabet, Martin Reck

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after plati... Tekijä Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromı́r Roubec, Luboš Petruželka, Libor Havel, Sujith Kalmadi, Jeffrey P. Ward, Zoran Andrić, Thierry Berghmans, David E. Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim G.J.V. Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey J. Langer

    Julkaistu 2023
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

    Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Tekijä Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

    CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer Tekijä Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, К. К. Лактионов, Tsung‐Ying Yang, Yan Yu, Terufumi Kato, Liyan Jiang, Busyamas Chewaskulyong, Sarayut Lucien Geater, Jean-Marc Maurel, Carlos A. Rojas, Toshiaki Takahashi, Libor Havel, Frances A. Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Neha P. Amin, Elena Armenteros-Monterroso, Xiangning Huang, Ammar Chaudhry, James Chih‐Hsin Yang

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries Tekijä Vincent D. de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brčić, Reinhard Büttner, Gabriela Fernandes, Libor Havel, Maximilian J. Hochmair, Paul Hofman, Annelies Janssens, Mikael Johansson, Léon C.L.T. van Kempen, Izidor Kern, Fernando López‐Ríos, Margreet Lüchtenborg, José Carlos Machado, Katja Mohorčič, Luis Paz‐Ares, Sanjay Popat, Aleš Ryška, Phillipe Taniere, Jürgen Wolf, Ed Schuuring, Anthonie J. van der Wekken

    Julkaistu 2024
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: